 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GT Biopharma, Inc. (NASDAQ:GTBP Free Report) Research analysts at HC Wainwright increased their Q3 2023 earnings per share estimates for shares of GT Biopharma in a research report issued to clients and investors on Tuesday, August 8th. HC Wainwright analyst R. Burns now expects that the company ...

HC Wainwright Weighs in on GT Biopharma, Inc.'s Q3 2023 Earnings (NASDAQ:GTBP)

HC Wainwright reissued their buy rating on shares of GT Biopharma (NASDAQ:GTBP  Free Report) in a research note published on Tuesday , Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for GT Biopharmas Q3 2023 earnings...

GT Biopharma (NASDAQ:GTBP) Earns "Buy" Rating from HC Wainwright

GT Biopharma, Inc. (NASDAQ:GTBP Free Report) Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of GT Biopharma in a research note issued to investors on Tuesday, August 8th. HC Wainwright analyst R. Burns expects that the company will post earnings of...

Equities Analysts Offer Predictions for GT Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:GTBP)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on GT Biopharma (GTBP Research Report) today and set a price target of $5.00. The co... H.C. Wainwright analyst Robert Burns reiterated a Buy rating on GT Biopharma (GTBP  Research Repo...

H.C. Wainwright Remains a Buy on GT Biopharma (GTBP)

GT Biopharma GAAP EPS of -$0.05

Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and initiate clinical trial activities on GTB-3650. BRISBANE, CALIFORNIA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- GT Biopharma...

GT Biopharma Reports Second Quarter 2023 Financial Results

RSSS Stock Price (10/4/2021 to 7/28/2023)

 Source:

 RSSS compared to NASDAQ Composite Index (10/4/2021 to 7/28/2023)

 Source:

 Stunning Increase in SG&A Expenses

 Stunning Increase in SG&A Expenses

 Net New Quarterly ARR

 Failure to Translate Revenue Growth and Margin Improvement into ...

Peter Derycz and Bristol Investment Fund Ltd. Issue Open Letter to Research Solutions, Inc. Shareholders

BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced that Dr. Jeffrey ...

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

GT Biopharma, Inc. (NASDAQ:GTBP  Get Rating) saw a significant decrease in short interest in May. As of May 31st, there was short interest totalling 133,300 shares, a decrease of 5.7% from the May 15th total of 141,400 shares. Based on an average daily trading volume, of 272,400 shares, the ...

GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Down 5.7% in May

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD Research Report), IGM Biosci... Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD Research Report), IGM ...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), IGM Biosciences (IGMS) and GT Biopharma (GTBP)

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Watchers	1,624
52-Wk Low	$0.1797
52-Wk High	$2.30

Market Cap	$10.16M
Volume (M)	1,709.00
52-Wk High	$2.30
52-Wk Low	$0.1797

GTBP GT Biopharma Inc

About

Feed

News

Earnings

Fundamentals